Live Biotherapeutic Product Market Dynamics Shaped by Increasing Awareness and Technological Advancements

The Live Biotherapeutic Product (LBP) Market is expected to grow at a 7.04 % CAGR during the forecast period for 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1300

Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global live biotherapeutic product (LBP) market are:
• Increasing incidence of digestive disorders
• Increasing healthcare expenditure and growing awareness
• Innovative technology

The following are the primary obstacles to the live biotherapeutic product (LBP) market's expansion:
• High manufacturing cost
• Strict regulatory compliance
• Lack of infrastructure

Future expansion opportunities for the global live biotherapeutic product (LBP) market include:
• Increasing strategic partnerships with biotech companies
• A growing interest in customized treatment
• Increased investment in research and development

Key Industry Insights & Findings from the Report:
• The live biotherapeutic product (LBP) market is expanding rapidly due to improvements in the study of the microbiome and rising spending on customized treatment.
• The market for live biotherapeutic products (LBP) is driven by technological developments, heightened awareness of healthcare, and supportive government policies.
• North America dominated the market and accounted for a revenue share of global revenue in 2023.
• One of the significant concerns restraining industry growth is the high manufacturing cost.

Market Analysis:
The live biotherapeutic product (LBP) market is experiencing significant growth, driven by rising demand for personalized therapeutics, increased awareness of gut health, and ongoing advancements in microbiome research. Expansion is further supported by the growing prevalence of immune-mediated disorders, metabolic diseases, and gastrointestinal conditions. Moreover, LBPs are emerging as a key segment within contemporary healthcare, fueled by substantial research and development investments, regulatory support for microbiome-based therapies, and an increasing shift toward alternatives to conventional antibiotic treatments.

List of Prominent Players in the Live Biotherapeutic Product (LBP) Market:
• Seres Therapeutics, Inc.
• Microbiotica
• Enterome
• Destiny Pharma plc
• Taisho Pharmaceutical Holdings
• AOBiome Therapeutics, Inc.
• Finch Therapeutics Group, Inc
• Ferring Pharmaceuticals
• Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals)
• MaaT Pharma
• Vedanta Biosciences Inc.
• OxThera AB
• Pendulum Therapeutics
• Caelus Health
• Quorum Innovations
• Sanofi S.A
• DermBiont, Inc.
• EnteroBiotix Ltd
• YSOPIA Bioscience
• Winclove Probiotics
• TargEDys
• Evelo Biosciences, Inc.
• BiomX
• Biomica Ltd.
• Scioto Biosciences, Inc.
• Lactobio A/S
• Takeda Pharmaceutical Co. Ltd.
• Second Genome Therapeutics
• Johnson and Johnson Inc.
• Kaleido Biosciences Inc.
• OptiBiotix Health Plc
• PureTech Health Plc
• Immuron Limited
• Naked Biome
• Synthetic Biologics
• ExeGi Pharma
• Nexbiome
• Mybiotics Pharma LTD.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Recent Developments:
• In January 2025, Microbiotica, a clinical-stage biopharma company that is creating a pipeline of oral precision microbiome medications known as live biotherapeutic products (LBPs), presented new information at the Keystone Symposia "Human Microbiome.
• In December 2024, DermBiont, a clinical-stage biotechnology company, provided updates on its development pipeline. These included the completion of enrollment in a Phase 2b clinical trial of SM-020 gel 1.0% for the treatment of SKs and expected clinical milestones. Vermont is developing targeted topical therapeutics to address patient needs in three of the most commonly diagnosed dermatological indications.
• In September 2024, to treat patients with recurrent glioblastoma, Enterome, a clinical-stage company that is creating first-in-class immunomodulatory medications for solid and liquid cancers and inflammatory diseases using its proprietary Mimicry platform, announced the database lock of its Phase 2 study of EO2401 in combination with an immune checkpoint inhibitor (nivolumab) +/-an anti-VEGF therapy (bevacizumab).

Live Biotherapeutic Product (LBP) Market Dynamics
Market Drivers: Increasing Incidence of Digestive Disorders
The live biotherapeutic product (LBP) market is primarily driven by the rising prevalence of gastrointestinal disorders and imbalances in intestinal microbiota. Growing demand for microbiota-targeted therapies aligns with the increasing incidence of digestive health conditions.

LBPs provide personalized, non-antibiotic treatment solutions that support gut health restoration and improve patient outcomes. Further, expanding awareness of the gut microbiome and ongoing research initiatives are fostering broader adoption of these therapies, reinforcing market growth.

Challenges: High Manufacturing Costs
Market expansion is constrained by the elevated costs associated with LBP production. The development of microbiome-based therapeutics requires specialized manufacturing infrastructure, advanced bioprocessing technologies, and stringent quality control measures, all of which contribute to higher production expenses. Additional financial considerations, including clinical trial requirements, regulatory compliance, and storage protocols, further limit product accessibility. Despite strong demand for microbiome-targeted interventions, these cost-related barriers impede market penetration and slow overall growth.

Regional Outlook: North America to Maintain Market Leadership
North America is projected to capture a significant revenue share and demonstrate robust compound annual growth rate (CAGR) during the forecast period. The region's growth is driven by increasing demand for personalized therapeutics, a rising prevalence of digestive disorders, and notable advancements in microbiome research.

Strong investments in research and development, a dynamic biotechnology sector, and heightened clinical trial activity further support market expansion. Additionally, strategic collaborations between biotechnology and pharmaceutical companies, coupled with growing consumer awareness of gut health, reinforce North America's position as a leading market for live biotherapeutic products.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1300

Segmentation of Live Biotherapeutic Product (LBP) Market-
By Product-
• VOWST (SER-109)
• REBYOTA
• Visbiome
• Other Pipeline Products
By Target Disease Indication-
• Recurrent C. Difficile Infection
• Irritable Bowel Syndrome (IBS)
• Ulcerative Colitis (UC)
• Antibiotic-associated diarrhea (AAD)
• Pouchitis
• Hepatic Encephalopathy (HE)
• Graft Versus Host Disease
• Necrotizing Enterocolitis
• Primary Hyperoxaluria
• Others
By Route of Administration-
• Hospitals
• Diagnostic Laboratories
• Oral Therapeutics
• Rectal Therapeutics
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/global-live-biotherapeutic-product-lbp-market/1300

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.